Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
30.48
-0.06 (-0.20%)
At close: Aug 1, 2025, 4:00 PM
30.50
+0.02 (0.07%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada.

Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.

The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy.

Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals logo
CountryCanada
Founded1996
IPO DateNov 5, 2014
IndustryBiotechnology
SectorHealthcare
Employees327
CEOIan Mortimer

Contact Details

Address:
200-3650 Gilmore Way
Burnaby, BC V5G 4W8
Canada
Phone604 484 3300
Websitexenon-pharma.com

Stock Details

Ticker SymbolXENE
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001582313
CUSIP Number98420N105
ISIN NumberCA98420N1050
Employer ID98-0661854
SIC Code2834

Key Executives

NamePosition
Ian C. Mortimer C.M.A., C.P.A., M.B.A.Interim Chief Financial Officer, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer and Director
Andrea DiFabio J.D.Chief Legal Officer and Corporate Secretary
Dr. Christopher John Kenney M.D.Chief Medical Officer
Dr. Matthew D. Ronsheim Ph.D.Chief Operating Officer
Shelley McClCoskey B.A.Executive Vice President of Human Resources
Dr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy and Innovation
Dr. James R. Empfield Ph.D.Executive Vice President of Drug Discovery
Darren S. Cline M.B.A.Chief Commercial Officer and Member of Executive Team

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jul 3, 20258-KCurrent Report
Jun 5, 20258-KCurrent Report
May 12, 202510-QQuarterly Report
May 12, 20258-KCurrent Report
Apr 24, 2025ARSFiling
Apr 24, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2025DEF 14AOther definitive proxy statements
Mar 17, 20258-KCurrent Report
Mar 7, 2025SCHEDULE 13G/AFiling